Skip to main content

Table 1 Basic demographic and clinical characteristics of all enrolled patients

From: Intravenous non-high-dose pantoprazole is equally effective as high-dose pantoprazole in preventing rebleeding among low risk patients with a bleeding peptic ulcer after initial endoscopic hemostasis

Variables Sustained Hemostasis (n = 324) Rebleeding (n = 89) p-value
Age (years) 64.8 ± 13.9 66.4 ± 13.2 0.812
Female gender, n (%) 87(26.8) 35(39.3) 0.022*
Hb (g/L) 96.7 ± 28.2 82.5 ± 24.1 < 0.001*
Creatinine 2.0 ± 2.3 3.6 ± 3.3 < 0.001*
Platelet (× 109/L) 197.4 ± 87.3 188.0 ± 129.0 0.031*
Use of NSAIDs, n (%) 29(9.0) 4(4.5) 0.170
Use of aspirin, n (%) 60(18.5) 9(10.1) 0.060
Use of clopidogrel, n (%) 38(11.7) 11(12.4) 0.870
Use of wafarin, n (%) 15(4.6) 5(5.6) 0.700
Shock on admission, n (%) 165(50.9) 53(59.6) 0.149
Coexisting illness, n (%)    
CKD III to V 126(38.9) 63(70.8) < 0.001*
COPD 22(6.8) 7(7.9) 0.725
CAD 62(19.1) 23(25.8) 0.166
DM 87(26.9) 37(41.6) 0.007*
CVA 54(16.7) 20(22.5) 0.206
Liver Cirrhosis 55(17.0) 12(13.5) 0.429
Rockall score 6.0 ± 1.6 6.8 ± 1.7 < 0.001*
Time to endoscope (h) 14.7 ± 13.6 18.5 ± 20.3 0.333
Ulcer size (cm) 1.0 ± 0.6 1.0 ± 0.6 0.884
Multiple ulcers, n (%) 105(32.4) 36(40.4) 0.156
High stigmata in Forrest classification, n (%) 316(97.5) 86(96.6) 0.640
PRBC BT(mL) 1203.2 ± 1640.4 2192.6 ± 2077.3 < 0.001*
Surgery, n (%) 1(0.3) 7(7.9) < 0.001*
Hospital stay(days) 11.5 ± 13.5 29.9 ± 46.0 < 0.001*
Mortality, n (%) 22(6.8) 26(29.2) < 0.001*
Bleeding related/Other causes 5/17 14/12  
  1. Abbreviations: OR, odds ratio; CI, confidence interval; Hb, hemoglobin; CKD, chronic kidney disease; NSAID, nonsteriodal anti-inflammatory drug; PPI, proton-pump inhibitor; DM, diabetes mellitus type 2; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; CVA, cerebrovascular accident; BT, blood transfusion. * p < 0.05